Designing a non-inferiority study in kidney transplantation: a case study

Area of Science:

• Immunology
• Pharmacology
• Clinical Trials

Background:

• Placebo-controlled trials are ethically unfeasible for organ transplant immunosuppressants.
• Non-inferiority trials are standard for evaluating new immunosuppressive drugs in kidney transplant recipients.
• Determining appropriate non-inferiority margins is challenging due to the lack of placebo data for established regimens.

Purpose of the Study:

• To propose and validate a method for deriving non-inferiority margins in immunosuppressant drug trials.
• To address the ethical and methodological challenges in establishing margins when a true placebo has not been studied.

Main Methods:

• Utilized a random-effect meta-regression analysis incorporating individual immunosuppressant components as covariates.
• Inferred the difference between a hypothetical placebo and the active control regimen.
• Derived the non-inferiority margin using a hybrid approach combining 95/95 and synthesis methods, applied to data from 51 trials (17,002 patients).

Main Results:

• The proposed meta-regression approach successfully derived a non-inferiority margin.
• The methodology was motivated by a large kidney transplant trial and submitted to the Food and Drug Administration (FDA).
• The FDA accepted the proposed non-inferiority margin and the underlying rationale.

Conclusions:

• The developed meta-regression framework provides a robust method for establishing non-inferiority margins in ethically constrained clinical trial settings.
• This approach ensures rigorous evaluation of new immunosuppressants while maintaining patient safety in organ transplantation.
• The FDA's acceptance validates the method's utility and reliability for regulatory submissions.